Sun Pharmaceutical Industries’ shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in women’s health. The deal diversifies Sun Pharma’s portfolio into women’s health and biosimilars, with analysts from Morgan Stanley and Motilal Oswal expressing bullish sentiment, while JM Financial remains cautious about long-term value creation.
